{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:47:18Z","timestamp":1648727238447},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bristol\u2013Myers Squibb\/Sanofi Pharmaceutical Partnership"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.ijcard.2011.10.087","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T17:56:16Z","timestamp":1321034176000},"page":"19-25","source":"Crossref","is-referenced-by-count":0,"title":["Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy"],"prefix":"10.1016","volume":"163","author":[{"given":"Satyendra","family":"Giri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2011.10.087_bb0005","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","volume":"120","author":"Kushner","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0010","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1161\/CIRCULATIONAHA.107.181940","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0015","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0025","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Early and late effects of clopidogrel in patients with acute coronary syndromes","volume":"107","author":"Yusuf","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0030","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(02)09894-X","article-title":"Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable Angina","volume":"360","author":"Fox","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0040","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI\u2013CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0045","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI\u2013CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0050","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0055","doi-asserted-by":"crossref","first-page":"66 e69-16","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjcard.2007.02.103","article-title":"Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status","volume":"100","author":"Weerakkody","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0065","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2010.04.022","volume":"160","author":"Chin","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0075","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0085","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0090","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0095","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jama.293.14.1759","article-title":"Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials","volume":"293","author":"De Luca","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0105","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1053\/euhj.2002.3160","article-title":"Platelet glycoprotein IIb\/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy","volume":"23","author":"Roffi","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0110","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0115","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0120","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/01.ATV.20.10.2316","article-title":"Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin","volume":"20","author":"Helft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1067\/mhj.2003.109","article-title":"Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial","volume":"145","author":"Gurbel","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0130","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0735-1097(03)00944-6","article-title":"Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)","volume":"42","author":"Chan","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0135","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.290.12.1593","article-title":"Evaluation of prolonged antithrombotic pretreatment (\u201ccooling-off\u201d strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial","volume":"290","author":"Neumann","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0140","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","volume":"112","author":"von Beckerath","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0145","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.0000161383.06692.D4","volume":"111","author":"Patti","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0150","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0155","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.jacc.2004.08.060","article-title":"Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization","volume":"44","author":"Kandzari","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0160","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2010.01.067","volume":"56","author":"Di Sciascio","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0165","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/CIRCULATIONAHA.108.776757","article-title":"Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study","volume":"118","author":"Collet","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0170","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jcin.2008.09.005","article-title":"The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial","volume":"1","author":"Gladding","year":"2008","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0175","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/eurheartj\/ehq081","article-title":"Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial","volume":"31","author":"Di Sciascio","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0180","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","article-title":"Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial","volume":"372","author":"Van't Hof","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0185","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCINTERVENTIONS.108.847996","article-title":"A comparison of abciximab and small-molecule glycoprotein IIb\/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials","volume":"2","author":"Gurm","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0190","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.292.3.362","article-title":"Early vs late administration of glycoprotein IIb\/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis","volume":"292","author":"Montalescot","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0195","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0200","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00129784-200404020-00003","article-title":"Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus","volume":"4","author":"Colwell","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0215","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0220","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0195-668X(03)00485-8","article-title":"Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE)","volume":"24","author":"Moscucci","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0002-9343(89)80690-4","article-title":"Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0230","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinte.165.7.784","article-title":"Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction","volume":"165","author":"Buresly","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0235","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.amjcard.2005.05.047","article-title":"Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events)","volume":"96","author":"Lim","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0240","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0245","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.jacc.2008.08.031","article-title":"Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis","volume":"52","author":"Berger","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0250","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11239-007-0016-x","article-title":"Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY\u2013TIMI 28","volume":"24","author":"McLean","year":"2007","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0260","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.jacc.2009.03.006","article-title":"Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial","volume":"53","author":"Ebrahimi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/hrt.2005.084830","article-title":"Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)","volume":"93","author":"Fox","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0270","author":"FDA Division of Cardiovascular and Renal Drugs"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0275","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jacc.2006.04.029","article-title":"Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery","volume":"48","author":"Mehta","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0280","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1592\/phco.27.8.1145","article-title":"Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative","volume":"27","author":"Bottorff","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0285","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.CIR.104.3.365","article-title":"Current concepts of the pathogenesis of the acute coronary syndromes","volume":"104","author":"Libby","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0290","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1161\/01.CIR.0000036595.92742.69","article-title":"Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era","volume":"106","author":"Seshadri","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0295","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.jacc.2005.06.083","article-title":"Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003","volume":"46","author":"Yang","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0300","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archsurg.133.4.442","article-title":"Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group","volume":"133","author":"Dacey","year":"1998","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0305","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0003-4975(99)00728-6","article-title":"Trends in rates of reexploration for hemorrhage after coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group","volume":"68","author":"Munoz","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0310","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehr151","article-title":"Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies","author":"Nijjer","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0315","first-page":"223","article-title":"Safety of glycoprotein IIb\/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery","volume":"20","author":"Cheng","year":"2004","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0320","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0325","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0330","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0335","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0340","series-title":"Transcatheter Cardiovascular Therapeutics 21st Annual Symposium","article-title":"The COGENT trial (abstract)","author":"Bhatt","year":"2009"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0345","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"Abraham","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0350","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1160\/TH09-06-0418","article-title":"Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis","volume":"103","author":"Sofi","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0355","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIR.0b013e3181ee08ed","article-title":"ACCF\/AHA Clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association","volume":"122","author":"Holmes","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0360","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0365","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0370","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON\u2013TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0375","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0380","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0385","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0390","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jacc.2010.07.004","article-title":"Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 2* loss of function polymorphism","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0395","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.087_bb0400","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08998280.2005.11928091","article-title":"The variability of platelet response to aspirin and clopidogrel: revisiting the CAPRIE, CURE, CREDO, and MATCH trials","volume":"18","author":"Myers","year":"2005","journal-title":"Proc (Bayl Univ Med Cent)"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527311019619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527311019619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T12:14:46Z","timestamp":1560946486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527311019619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0167527311019619"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2011.10.087","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}